Welcome to vnonline.co.uk

vnonline.co.uk provides the veterinary nursing profession with the latest news and industry developments, as well as events, resources, learning materials and careers.

Our website is dedicated to veterinary nurses and we strive to provide a platform where you can voice and explore your interests.

Not a member yet? Sign up for free!

Register for free with vnonline.co.uk to gain unlimited access to news, resources, jobs and much more!



Click here to become a member






Log in to vnonline

Forgot your password?

Posted: 23rd July 2018

New treatment for recurring malaria approved
P.vivax malaria is found mainly in the US, Latin America and some parts of Africa.
Single-dose Krintafel to prevent relapse of P. vivax malaria

A new vaccine for the treatment of recurring malaria has been approved by the United States Food and Drug Administration.

A press release issued by GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) said that single-dose Krintafel (tafenoquine) will be the first to prevent against a relapse of P. vivax malaria.  

“Today’s approval of Krintafel, the first new treatment for Plasmodium vivax malaria in over 60 years, is a significant milestone for people living with this type of relapsing malaria,” explained Dr Hal Barron, GSK chief scientific officer and president of research and development.

“Together with our partner, Medicines for Malaria Venture, we believe Krintafel will be an important medicine for patients with malaria and contribute to the ongoing effort to eradicate this disease.”

MMV chief executive officer Dr David Reddy hailed the US FDA’s approval of Krintafel as a ‘major milestone’ and a ‘significant contribution’ towards the global eradication of malaria.

“The world has waited decades for a new medicine to counter P. vivax malaria relapse,” he said. “Today, we can say the wait is over. Moreover, as the first ever single-dose for this indication, Krintafel will help improve patient compliance.

“We are proud to have worked side-by-side with GSK for more than a decade to reach this point. Our focus is now on working to ensure the medicine reaches the vulnerable patients that need it most.”

The most frequent and widely distributed causes of recurring malaria, p.vivax is one of the six species of parasite that commonly infects humans. Found mainly in the US, Latin America and some parts of Africa, it can lay dormant in the liver for several months or years after the infecting bite. 



Become a member or log in to add this story to your CPD history



Latest news | Careers | Events | Resources | Contact us | Terms and conditions | Data Protection and Privacy |Cookie policy | About us | Copyright
© 2024 Vision Media, all rights reserved. vnonline.co.uk is not responsible for the content of external websites.